Global Next-Generation Breast Cancer Diagnostic and Screening Market to grow with a CAGR of 10.30%
Increasing healthcare
infrastructure and a supportive regulatory environment are the major drivers
for the Global Next-Generation Breast Cancer Diagnostic and Screening Market.
According to TechSci Research
report, “Global Next-Generation Breast Cancer Diagnostic and Screening
Market Industry Size, Share,
Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Next-Generation Breast
Cancer Diagnostic and Screening Market has valued at USD 2.90 billion in 2022
and is anticipated to witness a robust growth in the forecast period with a
CAGR of 10.51% through 2028. This can be due to collaborations and partnerships
among leading companies with a diverse approach to merge the expertise of
individual companies and to strengthen their position in the market.
The aging population is a
driver for the global next-generation breast cancer diagnostic and screening
market. Breast cancer risk significantly increases with age. Most breast cancer
cases occur in women aged 50 and older. As the global population continues to
age, there is a higher prevalence of individuals at an age when breast cancer
risk is elevated. Healthcare guidelines often recommend regular breast cancer
screening for women aged 50 and older. Mammography and other screening methods
become increasingly important as women age, as early detection is associated
with better treatment outcomes. Next-generation breast cancer diagnostic and
screening methods aim to improve early detection, which is particularly crucial
in older populations. Early detection allows for timely treatment interventions
that can be less invasive and have better prognoses. The global geriatric
population is expanding due to increased life expectancy. As individuals live
longer, the likelihood of developing age-related diseases like breast cancer
also rises, driving the demand for advanced diagnostic and screening services.
Browse over XX market data Figures and spread
through 110 Pages and an in-depth TOC on "Next-Generation Breast Cancer Diagnostic and Screening Market.”
The
global market for next-generation breast cancer diagnostics and screenings was
significantly impacted by COVID-19. Research on next-generation breast cancer
diagnostic and screening was put on hold because of a noticeable shift towards
research activities for treating and diagnosing COVID-19.
In
March 2023, The RaDaR assay, a liquid biopsy test for molecular/minimal
residual disease (MRD), has been made commercially available, according to
NeoGenomics, Inc., a top provider of oncology testing and international
contract research services. The circulating tumour DNA (ctDNA) that is still
present after surgery or other cancer treatments is known as MRD. The CHiRP
study, published at ASCO 2022, and data presentations for the TRACER and
cTRAK-TN study cohorts at the most recent SABCS conference are just two recent
publications that demonstrate the clinical utility of the RaDaR test,
particularly in the breast cancer space. The RaDaR assay is a highly sensitive,
personalized, tumor-informed technique that monitors up to 48 tumor-specific
mutations in cell-free DNA (cfDNA) found in the blood plasma of cancer
patients.
Clinical
validation is a significant challenge in the global next-generation breast
cancer diagnostic and screening market. Clinical validation refers to the
rigorous process of demonstrating that a diagnostic or screening test is
accurate, reliable, and clinically meaningful for its intended purpose. To establish the accuracy and reliability of a diagnostic
test, clinical studies must enroll enough participants. Achieving a large
enough sample size with statistical power can be challenging, especially for
rare breast cancer subtypes. Long-term
follow-up data are essential to assess the test's performance over time. These
data are crucial for evaluating the test's ability to predict outcomes, such as
disease recurrence or response to treatment. Clinical validation studies often require a "gold
standard" for comparison, such as histopathology or clinical outcomes. In
the case of breast cancer, obtaining biopsy and pathology data for comparison
can be challenging, especially for early-stage or asymptomatic cases.
Global Next-Generation
Breast Cancer Diagnostic and Screening Market segmentation is based on Technology,
Biomarker, Cancer Sub Type, Offering, End User, and Region.
Based on Cancer Sub Type,
Global Next-Generation Breast Cancer Diagnostic and Screening Market is
segmented into Luminal A, Luminal B, Triple Negative/Basal Like, Human
Epidermal Growth Factor Receptor 2 (HER-2) Enriched. Luminal B breast cancer
is one of the molecular subtypes of breast cancer. It is characterized by
certain molecular and genetic features that help classify and understand the disease
better.
Breast cancer is not a single disease but rather a
group of diseases with varying characteristics. Molecular subtyping is a method
of categorizing breast cancer based on specific genetic and molecular features
that affect the behavior and response to treatment. Luminal B breast cancer
is characterized by the presence of hormone receptors on the surface of cancer
cells. Specifically, it is positive for estrogen receptor (ER) and/or
progesterone receptor (PR). These receptors allow the cancer cells to respond
to estrogen and progesterone hormones, which can promote their growth. Luminal B breast cancer
can also be HER2-positive or HER2-negative. HER2 (human epidermal growth factor
receptor 2) is a protein that, when overexpressed or amplified, can lead to
more aggressive tumor growth. HER2-positive Luminal B breast cancer tends to be
more aggressive and may require targeted therapies.
Based on Region, North America dominated the Global Next-Generation
Breast Cancer Diagnostic and Screening Market. North America has a
relatively high incidence of breast cancer. This high prevalence of the disease
has driven the demand for advanced diagnostic and screening tools, leading to a
robust market for breast cancer diagnostics. In North America, there is
generally better access to healthcare services, including cancer screening and
diagnostics, compared to many other regions. Health insurance coverage and
public health programs facilitate early detection and diagnosis. North American
institutions actively participate in clinical trials related to breast cancer
diagnostics and screening. Collaboration between research institutions,
healthcare providers, and industry partners accelerates the development and
adoption of new technologies.
Asia-pacific region to fastest growth in
the Global Next-Generation Breast Cancer Diagnostic and Screening Market. Breast
cancer rates are rising in many countries across the Asia-Pacific region,
driven by factors such as changing lifestyles, aging populations, and increased
awareness. As breast cancer becomes more prevalent, there is a growing demand
for advanced diagnostic and screening services. APAC is the most populous
region globally, with a significant proportion of women at risk of breast cancer
due to age and other risk factors. The sheer size of the population contributes
to a substantial pool of potential patients for breast cancer screening and
diagnostics. Rapid urbanization in many APAC countries has led to lifestyle
changes associated with increased breast cancer risk, such as sedentary
lifestyles, unhealthy diets, and delayed childbearing. These factors contribute
to the rising incidence of breast cancer and the need for screening.
Some of the major companies
operating in the Global Next-Generation Breast Cancer Diagnostic and
Screening Market include:
- Abbott
Laboratories
- Agendia
Inc.
- Agilent
Technologies, Inc.
- Bio-Rad
Laboratories, Inc.
- Genomics
Co., Ltd.
- CENTOGENE
N.V
- Danaher
Corporation
- Exact
Sciences Corporation
- F.
Hoffmann-La Roche Ltd.
- Illumina,
Inc.
- Thermo
Fisher Scientific Inc.
- Lucence
Diagnostics Pte Ltd.
Download Free Sample Report
Customers can also request 10% free
customization on this report..
“Certain
areas, particularly in North America, are projected to exert significant demand
for breast cancer diagnosis. The growth in the competitive landscape and the
presence of well-established companies in the market, committed to enhance the overall
wellbeing of people each year, are expected to contribute to a remarkable
growth of the Global Next-Generation Breast Cancer Diagnostic and Screening
Market in the forecast period," said Mr. Karan Chechi, Research Director
with TechSci Research, a research-based Global management consulting firm.
Next-Generation Breast Cancer Diagnostic and
Screening Market – Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2018-2028, Segmented by Technology (Real-Time PCR, Immunohistochemistry (IHC), Next-Generation
Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH), others), by
Biomarker (BRCA1/2, ER/PR Receptors, HER-2, Others), by Cancer Sub-Type
(Luminal A, Luminal B, Triple Negative/Basal Like, Human Epidermal Growth
Factor Receptor 2 (HER-2) Enriched), by Offering (Products, Services), by End
User (Hospitals and Clinics, Diagnostic Centers and Reference Labs, Academic
and Research Institutes), by region, and
Competition evaluated the future growth
potential of Global Next-Generation Breast Cancer Diagnostic and Screening
Market and provides statistics & information on market size, structure, and
future market growth. The report intends to provide innovative market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Next-Generation Breast Cancer
Diagnostic and Screening Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com